Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
19 January 2007 - 7:20PM
PR Newswire (US)
BERLIN, Germany, January 19 /PRNewswire-FirstCall/ -- Bayer
Schering Pharma AG (NYSE:SHR) has signed a license and option
agreement with Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co.,
Ltd., and the National Institute of Radiological Sciences (NIRS),
Japan, to develop novel imaging compounds for the detection of
neurodegenerative diseases such as Alzheimer's disease, Parkinson's
disease and other disorders also associated with neuroinflammation
such as multiple sclerosis. "We are convinced that innovations in
molecular imaging have the potential to fundamentally improve the
diagnosis of neurodegenerative disorders, particularly Alzheimer's
disease. Bayer Schering Pharma is already pursuing the development
of tracers targeting amyloid plaques, a hallmark of this disease.
Imaging of neuroinflammation as another important pathology will
excellently complement these activities," said Dr. Hans Maier, Head
of Business Unit Diagnostic Imaging at Bayer Schering Pharma. "This
agreement underscores our commitment to Alzheimer patients by
developing innovative diagnostic methods for the early detection of
the disease." Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co.,
Ltd. and the National Institute of Radiological Sciences (NIRS)
jointly own patent rights for a compound class that may be applied
for various non-invasive imaging technologies, such as positron
emission tomography (PET) scanning. Under the terms of the
agreement Bayer Schering Pharma receives worldwide exclusive rights
to develop and market the respective products for use with PET
scanning technology. Worldwide representative epidemiological
surveys* estimate that 24.3 million people suffer from dementia
today with about 4.6 million new cases occurring every year. The
number of people affected will double every 20 years to an
estimated 81.1 million by 2040. Of these cases 50% to 75 % are
associated with Alzheimer's disease. * Ferri C.P. et al. Global
prevalence of dementia: a Delphi consensus study. Lancet 2005;
366:2112-17 Bayer Schering Pharma AG is a worldwide leading
specialty pharmaceutical company. Its research and business
activities are focused on the following areas: Women's Healthcare,
Diagnostic Imaging, Specialized Therapeutics,
Hematology/Cardiology, Primary Care, and Oncology. With innovative
products, Bayer Schering Pharma aims for leading positions in
specialized markets worldwide. Using new ideas, Bayer Schering
Pharma aims to make a contribution to medical progress and strives
to improve the quality of life. Additional Information About Taisho
Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd. is the
leading non-prescription pharmaceutical company in Japan and has
also been strengthening its research and development efforts in the
area of prescription drugs. Taisho continues efforts to strengthen
its prescription drug business through expansion of its novel
original R&D and active collaboration with domestic and foreign
pharmaceutical companies. About Nihon Nohyaku Co., Ltd., Nihon
Nohyaku Co., Ltd. is an agrochemical company listed on the Tokyo
Stock exchange. Its core business is crop protection. About the
National Institute of Radiological Sciences (NIRS) The National
Institute of Radiological Sciences (NIRS) in Japan is a state-owned
research institution. This press release has been published by
Global Corporate Communications of Bayer Schering Pharma AG,
Berlin, Germany. Your Contacts: Oliver Renner, Tel.
+49-30-468-12431 E-Mail: Dr. Claudia Schmitt, Tel: +49-30-468-15805
E-Mail: Important information from Bayer Schering Pharma AG: Bayer
Schering Pharma Aktiengesellschaft (formerly Schering
Aktiengesellschaft) has filed a solicitation/recommendation
statement with the U.S. Securities and Exchange Commission with
respect to the offer of cash compensation by Bayer Schering GmbH
(formerly Dritte BV GmbH), a wholly owned subsidiary of Bayer
Aktiengesellschaft, in connection with the domination and profit
and loss transfer agreement between Bayer Schering GmbH and Bayer
Schering Pharma Aktiengesellschaft. Holders of ordinary shares and
American depositary shares of Bayer Schering Pharma
Aktiengesellschaft are advised to read such
solicitation/recommendation statement because it contains important
information. Holders of ordinary shares and American depositary
shares of Bayer Schering Pharma Aktiengesellschaft may obtain such
solicitation/recommendation statement and other filed documents
free of charge at the U.S. Securities and Exchange Commission's
website (http://www.sec.gov/) and at Bayer Schering Pharma
Aktiengesellschaft's website (http://www.schering.de/). Certain
statements in this press release that are neither reported
financial results nor other historical information are
forward-looking statements, including but not limited to,
statements that are predictions of or indicate future events,
trends, plans or objectives. Undue reliance should not be placed on
such statements because, by their nature, they are subject to known
and unknown risks and uncertainties and can be affected by other
factors that could cause actual results and Bayer Schering Pharma
AG's plans and objectives to differ materially from those expressed
or implied in the forward-looking statements. Certain factors that
may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission.
Bayer Schering Pharma AG undertakes no obligation to update
publicly or revise any of these forward-looking statements, whether
to reflect new information or future events or circumstances or
otherwise. DATASOURCE: Bayer Schering Pharma AG CONTACT: Your
Contacts: Oliver Renner, Tel. +49-30-468-12431, E-Mail: ; Dr.
Claudia Schmitt, Tel: +49-30-468-15805, E-Mail:
Copyright
Schering Aktiengesel (NYSE:SHR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Schering Aktiengesel (NYSE:SHR)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Bank of America Corp. Strategic Accelerated Redemption Securities Linked TO The S&P 500 Index (New York Stock Exchange): 0 recent articles
More - News Articles